Hyundai ADM Bio lnc, formerly ADM Korea Inc, is a Korea-based company that primarily provides clinical trial services. The Company primarily provides clinical trial-related services to pharmaceutical companies, bio ventures, and others. In addition, the Company provides post-marketing surveillance services. In addition, the Company develops and sells deoxyribonucleic acid (DNA) needle patches.

Employees

160

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-04-17	14,030.00 ₩	-7.94%	5,028,417
26-04-16	15,240.00 ₩	-9.55%	11,789,100
26-04-15	16,850.00 ₩	+10.71%	5,076,513
26-04-14	15,220.00 ₩	+3.12%	3,620,299
26-04-13	14,760.00 ₩	-0.34%	1,503,198

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Korea S.E. Other stock markets 2026-04-17			5-day change	1st Jan Change
14,030.00 ^KRW	-7.94%		-5.27%	+489.50%

Apr. 17	Penetrium Bioscience Unveils Breakthrough Mechanism for Targeted Cancer Therapy	CI
25-06-25	Hyundai ADM Bio Inc. announced that it has received KRW 3.981 billion in funding from CnPharm Co., Ltd. and another investor	CI

Capitalization	130B 89.22M 75.58M 69.54M 65.81M 122M 8.26B 124M 814M 319M 4B 335M 328M 14.1B	P/E ratio 2023	-13.8x	P/E ratio 2024	-3.53x
Enterprise value	134B 91.58M 77.57M 71.38M 67.55M 125M 8.47B 127M 836M 328M 4.11B 344M 336M 14.48B	EV / Sales 2023	1.88x	EV / Sales 2024	7.52x
Free-Float	2.63%	Yield 2023 *	-	Yield 2024	-

Apr. 17	Penetrium Bioscience Unveils Breakthrough Mechanism for Targeted Cancer Therapy	CI
25-06-25	Hyundai ADM Bio Inc. announced that it has received KRW 3.981 billion in funding from CnPharm Co., Ltd. and another investor	CI
25-06-16	Hyundai ADM Bio To Conduct Capital Increase Of 4 Billion Won For Operational Funds	RE
25-06-15	Hyundai ADM Bio Inc. announced that it expects to receive KRW 3.981 billion in funding from CnPharm Co., Ltd. and another investor	CI
25-05-14	Hyundai ADM Bio Wins 991 Million Won Order	RE
25-05-13	Hyundai ADM Bio Voluntary Withdraws IND for Clinical Study of Docetaxel Combination Cancer Therapy to Focus on Immunotherapy Strategy	CI
25-03-27	Hyundai ADM Bio Demonstrates Anti-Metastatic Effect of 'PenetriumTM' in TNBC Preclinical Study	CI
25-03-12	Hyundai ADM Bio Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-01-22	Hyundai ADM Bio Unveils A New Paradigm in Cancer Treatment	CI
24-11-14	Hyundai ADM Bio Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
24-07-11	ADM Korea Announces Niclosamide-Based Metabolic Anticancer Drug's First Clinical Trial Target as 'Prostate Cancer Patients Resistant to Hormone Therapy'	CI
24-06-26	ADM Korea Inc. announced that it has received KRW 12 billion in funding from Sangsangin Savings Bank, Sangsangin Plus Savings Bank Co.,Ltd. and other investors	CI
24-06-02	ADM Korea Inc. announced that it expects to receive KRW 10 billion in funding from Inthemoney. Inc	CI

1 day	-7.94%
1 week	-5.27%
Current month	+26.97%
1 month	-13.40%
3 months	+460.08%
6 months	+336.39%
Current year	+489.50%

Penetrium Bioscience Inc. Stock

Equities

A187660

KR7187660006

Biotechnology & Medical Research

Valuation: Penetrium Bioscience Inc.

Chart: Penetrium Bioscience Inc.

Latest news: Penetrium Bioscience Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Penetrium Bioscience Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	13,690	18,440
1 month	9,870	18,440
Current year	2,325	21,500
1 year	1,118	21,500
3 years	855	21,500
5 years	855	21,500
10 years	855	21,500

Manager	Title	Age	Since
Kwang-Hee Kim CEO	Chief Executive Officer	60	-
Taek-Sung Kim CEO	Chief Executive Officer	61	-

Director	Title	Age	Since
Taek-Sung Kim BRD	Director/Board Member	61	-
Kwang-Hee Kim BRD	Director/Board Member	60	-
Geun-Woo Jin BRD	Director/Board Member	46	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
PENETRIUM BIOSCIENCE INC.	-7.94%	-5.27%	+697.61%	+1,178.36%	526M
LONZA GROUP AG	+2.22%	+5.51%	+0.78%	-7.33%	48.69B
BEONE MEDICINES AG	+0.99%	+4.59%	+40.22%	+21.40%	35.92B
REVOLUTION MEDICINES, INC.	-0.43%	+54.13%	+304.33%	+512.40%	31.26B
CELLTRION, INC.	-0.72%	+3.91%	+37.10%	+32.51%	29.77B
IQVIA HOLDINGS INC.	+2.62%	+5.45%	+22.62%	-12.96%	29.62B
ASCENDIS PHARMA A/S	+0.63%	+2.17%	+48.12%	+200.79%	15.1B
MEDPACE HOLDINGS, INC.	+0.96%	+5.48%	+75.71%	+171.60%	14.87B
EUROFINS SCIENTIFIC SE	+0.87%	+8.85%	+40.89%	+13.75%	14.5B
REGENCELL BIOSCIENCE HOLDINGS LIMITED	-6.22%	-0.52%	+3,641.35%	+3,861.59%	14.18B
Average	-0.70%	+8.33%	+490.87%	+597.21%	23.44B
Weighted average by Cap.	+0.56%	+11.08%	+286.66%	+333.40%

	2023	2024
Net sales	13.79B 9.44M 8M 7.36M 6.96M 12.91M 873M 13.13M 86.17M 33.79M 423M 35.41M 34.67M 1.49B	9.74B 6.67M 5.65M 5.2M 4.92M 9.12M 617M 9.28M 60.89M 23.88M 299M 25.02M 24.5M 1.05B
Net income	-2.97B -2.03M -1.72M -1.58M -1.5M -2.78M -188M -2.83M -18.56M -7.28M -91.2M -7.63M -7.47M -321M	-20.1B -13.76M -11.65M -10.72M -10.15M -18.81M -1.27B -19.14M -126M -49.24M -617M -51.6M -50.53M -2.17B
Net Debt	-18.28B -12.52M -10.6M -9.75M -9.23M -17.11M -1.16B -17.41M -114M -44.8M -561M -46.95M -45.97M -1.98B	3.44B 2.36M 2M 1.84M 1.74M 3.22M 218M 3.28M 21.53M 8.44M 106M 8.85M 8.66M 373M